EMDR-Based Mobile Apps Show Promise in Reducing PTSD Symptoms
KEW, VICTORIA, AUSTRALIA, May 27, 2025 / EINPresswire.com / -- A new series of smartphone apps developed by Australian psychologist Mark Grant is delivering promising results for people living with Posttraumatic Stress Disorder ( PTSD ). In a recent pilot study, users who engaged with the apps regularly over three months experienced a 40% reduction in PTSD symptoms, and significantly decreased comorbid health problems.
With rates of PTSD on the rise globally due to war, the pandemic, and social unrest, these accessible and affordable tools could mark a breakthrough in how trauma is managed in everyday life.
The Healing Trauma App Series ( HTAS ) is designed to address four of the most common problems associated with PTSD: anxiety, medically unexplained pain, insomnia and decreased self-confidence.
1. Anxiety Release App: Targets anxiety associated with PTSD.
2. Overcoming Pain App: Targets pain/medically unexplained symptoms associated with PTSD.
3. Sleep Restore App: Addresses insomnia associated with PTSD.
4. Calm and Confident App: Addresses the impact of trauma and PTSD on identity.
In the pilot study, participants who used the app series consistently over three months experienced a remarkable 40% reduction in PTSD symptoms. Physical symptoms commonly linked to trauma, such as sleep disturbances, fatigue and chronic pain, also showed significant improvement. These positive outcomes were largely maintained at a six-month follow-up.
The apps proved effective across a wide range of trauma experiences, including childhood abuse, assault, car accidents and medical trauma. Many users found it helpful to use different apps for different issues, tailoring their support to their needs. Notably, participants were more likely to stick with the program when a therapist recommended the apps, highlighting the importance of professional guidance alongside digital support. A larger follow-up study is being planned.
The apps are built on the principles of Eye Movement Desensitization and Reprocessing ( EMDR ), a cutting-edge trauma therapy that works by helping the brain 'rewire' itself. EMDR targets the neural pathways that store traumatic memories and pain by combining focused attention with rhythmic, bilateral stimulation, such as sound or movement. This dual approach activates both emotional and rational parts of the brain, promoting healing from the inside out.
Because it works directly with the brain's natural ability to adapt (neuroplasticity), EMDR has been shown to deliver faster results than traditional therapies like exposure therapy. One app user shared:
'As soon as I hear the bilateral stimulation, I seem to calm down. Having the first calm day in my life, it's a bit unnerving.'
Each app in the series is designed to be used on an 'as-needed' basis, giving users the flexibility to manage whatever symptoms they're experiencing in the moment, whether it's anxiety, insomnia, pain, or low confidence. Since trauma symptoms can shift day to day, or even hour to hour, having access to all four apps gives users a personalised toolkit for support whenever they need it.
The apps are affordably priced at just USD $5.00 each, or users can access the full bundle for only USD $10.00. In a show of global solidarity, 1,000 downloads were recently donated to Ukrainian citizens and soldiers affected by war-related trauma.
For more information visit https://www.traumaapps.com.
ENDS
For more information, contact Mark on (+61) 0402 122 173 or email [email protected]
Zhai Y, Du X. Trends in Diagnosed Posttraumatic Stress Disorder and Acute Stress Disorder in US College Students, 2017-2022. JAMA Netw Open. 2024;7(5):e2413874. doi:10.1001/jamanetworkopen.2024.13874
Mark Grant
Mark Grant MA
+61 402 122 173
[email protected]
Visit us on social media:
Facebook
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
15 minutes ago
- Health Line
What Are the Complications and Long-Term Risks of Meningitis
Meningococcal meningitis can lead to serious complications, such as hearing loss, scarring, or even amputation. Getting treatment early can prevent these outcomes. Meningitis is a condition characterized by swelling of the lining of the brain and spinal cord. It can be caused by viruses, bacteria, or fungi. Meningococcal meningitis occurs when the bacterium Neisseria meningitidis infects the meninges (tissues around the brain and spinal cord). Neisseria meningitidis can also infect the bloodstream. Meningococcal meningitis and bloodstream infections are two common types of meningococcal disease. An infection of the meninges can cause a dangerous buildup of pressure on the brain. Symptoms of infection may include: headache stiff neck confusion sensitivity to light high fever nausea skin rash vomiting Main complications of meningitis Meningococcal disease is fatal in about 10 to 15 people out of every 100 receiving a diagnosis, according to the Centers for Disease Control and Prevention (CDC). The disease may lead to long-term complications in about 20% of those with the condition. Among the possible complications of meningococcal disease are: chronic pain scarring amputation hearing impairment vision impairment motor function impairment post-infection inflammatory syndromes arthritis post-traumatic stress disorder (PTSD) anxiety depression Some complications of meningococcal disease that require immediate medical attention are: septic shock seizures purpura fulminans (skin rash and possible organ failure) hydrocephalus (fluid buildup on the brain) cerebral venous sinus thrombosis (stroke) Waterhouse-Friderichsen syndrome (bleeding into the adrenal glands) subdural empyema (pus between layers of the brain's protective tissue) Bacteremia and septicemia One type of meningococcal disease is an infection of the tissues around the brain and spinal cord (meningococcal meningitis). Neisseria meningitidis can also infect the bloodstream, resulting in bacteremia or septicemia. Meningococcal septicemia is a dangerous form of bloodstream infection. The bacteria multiply and release toxins that can damage blood vessel linings. Bleeding into the skin or organs may occur. A characteristic dark purple rash may develop in the later stages. Other symptoms may include: fatigue vomiting cold hands and feet chills diarrhea rapid breathing severe aches or pains in the muscles, joints, chest, or belly. This form of infection also requires immediate care and can cause some of the most serious complications of meningococcal disease, such as: necrosis (skin death) hearing loss deafness seizures amputation skin scarring impaired blood flow to the organs heart failure Diagnosis and treatment Diagnosing meningococcal disease can be a challenge because early symptoms look like other conditions. When a doctor suspects meningococcal disease, they can test for the presence of bacteria in cerebrospinal fluid or blood. Getting a sample of spinal fluid requires a lumbar puncture procedure. Antibiotics are the mainstay of treatment. Doctors typically start antibiotic treatment as soon as they suspect meningococcal disease to reduce the risk of serious complications. In some cases, someone with meningococcal disease will require hospitalization. Some types of care they might receive include: intensive care unit (ICU) admission and medications to help maintain a stable blood pressure, especially if it drops too low due to severe infection intravenous (IV) fluids and rehydration breathing and airway support blood transfusions wound and skin care How common are meningitis outbreaks? According to the CDC, there were 438 confirmed and probable cases of meningococcal disease in the United States in 2023. The recent rise in cases has been mostly linked to the serogroup Y strain of Neisseria meningitidis, one of several strains that can cause meningococcal disease. Serogroup Y has been spreading more frequently in recent years, contributing to localized outbreaks. Some groups are more at risk than others. Infants, teens, and young adults tend to have higher rates of developing an infection, as do people with certain medical conditions or those living in close quarters like college dorms or military barracks. Outbreaks also tend to occur in communities with lower vaccination rates or limited access to preventive care. That's why it's so important to recognize the signs, respond quickly to symptoms, and stay up to date with recommended vaccines, especially for people at a higher risk. Vaccines are available that help protect against different types of meningococcal disease, including the strains most often linked to outbreaks, such as serogroups A, C, W, Y, and B.
New York Times
15 minutes ago
- New York Times
MRNA, Used in Covid Shots, May Help Rid the Body of H.I.V.
The technology that powered Covid vaccines may also lead scientists to a cure for H.I.V. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary, and so far, has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of Covid vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting H.I.V. 'mRNA is just this miraculous — I really do think miraculous — tool to deliver things that you want into places that were not possible before,' said Dr. Sharon Lewin, director of the Cumming Global Center for Pandemic Therapeutics in Melbourne, who led the study. Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr., have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also canceled a nearly $600 million contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. Want all of The Times? Subscribe.
Business of Fashion
an hour ago
- Business of Fashion
De Beers Draws Interest From Ex-CEOs as Anglo Starts Sale
Anglo American Plc is about to begin a formal sales process for De Beers, after receiving indications of interest from potential buyers that include two former chief executives of the iconic diamond miner. An exit from De Beers represents the final step in a sweeping restructuring plan outlined by Anglo CEO Duncan Wanblad last year as the company fended off a takeover approach from BHP Group. Anglo has already agreed to sell its coal and nickel mines and unbundled its platinum business this week. Former De Beers bosses Gareth Penny and Bruce Cleaver are both leading groups that are potential buyers, as is Australian mining veteran Michael O'Keeffe, according to people familiar with the matter. Anglo is working with advisers who are preparing to start the process, said the people, who asked not to be identified discussing private information. Anglo American declined to comment, as did Penny and Cleaver. O'Keeffe could not be reached for comment. Anglo has waited to sell De Beers as the diamond industry grappled with its deepest crisis in decades, after a collapse in Chinese demand and fierce competition from synthetic stones. Anglo wrote down the value of the unit for a second time in February, to about $4.9 billion. Anglo shares rose as much as 4 percent and traded at 2,314 pence by 2:14 p.m. in London. But while prices for rough diamonds have slumped, Anglo's executives still see De Beers as a trophy asset — the company has said it will be patient in finding a buyer and doesn't want to destroy value by moving too quickly. The diamond market is now showing signs of stabilising, although President Donald Trump's trade war has created fresh uncertainty and disruption. Anglo is also examining options for an initial public offering or demerger of De Beers. However, a sale is the preferred and most likely option, the people said. A successful sale of De Beers would mark a significant step forward in Wanblad's efforts to streamline Anglo's business and revive its fortunes after a series of missteps that left the century-old miner vulnerable to BHP's takeover attempt. Cleaver, currently chairman of emerald miner Gemfields Group Ltd., was CEO of De Beers until 2023. He's in the advanced stages of arranging funding for a potential offer, two of the people said. Penny is also a former De Beers CEO, who ran the company when the billionaire Oppenheimer family still owned a stake. He led De Beers through the global financial crisis, when it was forced to shutter mines and tap its shareholders in an emergency rights issue, and is currently chairman of asset manager Ninety One Plc. O'Keeffe is a mining veteran who sold coal producer Riversdale Mining to Rio Tinto Group for $3.7 billion in 2011. He's chairman of Burgundy Diamond Mines Ltd., an Australia-based company which operates the Ekati mine in Canada, once owned by BHP Group. By Thomas Biesheuvel, Dinesh Nair Learn more: De Beers is Closing Its Man-Made Diamond Jewellery Business De Beers is closing its lab-grown diamond jewellery business amid declining synthetic gem values and a company restructuring.
